About AVT
Browse Articles
Customer Services

Original article

Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD)

Rimke Bijker, Nagalingeswaran Kumarasamy, Sasisopin Kiertiburanakul, Sanjay Pujari, Wilson Lam, Romanee Chaiwarith, Wing W Wong, Adeeba Kamarulzaman, Pacharee Kantipong, Anchalee Avihingsanon, Kinh V Nguyen, Junko Tanuma, Oon Tek Ng, Benedict LH Sim, Tuti P Merati, Jun Y Choi, Rossana Ditangco, Evy Yunihastuti, Ly P Sun, Cuong D Do, Jeremy Ross, Matthew Law, the TREAT Asia HIV Observational Database (TAHOD) of IeDEA Asia-Pacific

Corresponding author name: Rimke Bijker
Corresponding author e-mail: rbijker@kirby.unsw.edu.au

Citation: Antiviral Therapy 2019; 24:271-279
doi: 10.3851/IMP3298

Date accepted: 11 February 2019
Date published online: 05 March 2019


Background: We aimed to project the 10-year future incidence of cardiovascular disease (CVD) and model several intervention scenarios based on a multi-site Asian HIV-positive cohort.

Methods: Analyses were based on patients recruited to the TREAT Asia HIV Observational Database (TAHOD), consisting of 21 sites in 12 countries. Patients on triple antiretroviral therapy (ART) were included if they were alive, without previous CVD, and had data on CVD risk factors. Annual new CVD events for 2019–2028 were estimated with the D:A:D equation, accounting for age- and sex-adjusted mortality. Modelled intervention scenarios were treatment of high total cholesterol, low high-density lipoprotein cholesterol (HDL) or high blood pressure, abacavir or lopinavir substitution, and smoking cessation.

Results: Of 3,703 included patients, 69% were male, median age was 46 (IQR 40–53) years and median time since ART initiation was 9.8 years (IQR 7.5–14.1). Cohort incidence rates of CVD were projected to increase from 730 per 100,000 person-years (pys) in 2019 to 1,432 per 100,000 pys in 2028. In the modelled intervention scenarios, most events can be avoided by smoking cessation, abacavir substitution, lopinavir substitution, decreasing total cholesterol, treating high blood pressure and increasing HDL.

Conclusions: Our projections suggest a doubling of CVD incidence rates in Asian HIV-positive adults in our cohort. An increase in CVD can be expected in any ageing population, however, according to our models, this can be close to averted by interventions. Thus, there is an urgent need for risk screening and integration of HIV and CVD programmes to reduce the future CVD burden.


Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.